SBIR/STTR Research Award
Development of small near-infrared laser system capable of improving immune respo
Award amount
$146,905Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SEMINEX CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-235
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make vaccines work better is to treat the skin with a brief exposure to a non-harmful laser light and then introduce the vaccine at that skin site. This approach can result in better vaccine responses without the need for chemical adjuvants. Until now, these responses have been generated using large and relatively expensive bench top devices. Recently, low-power, near-infrared (NIR) laser light has also been shown to significantly enhancing vaccine responses. This would make it possible to use small, low-cost NIR laser systems to enhance vaccines that would be practical in the clinical setting. There are currently
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients